MarketPR
A milestone payment from Takeda and the first full quarter of ICOTYDE commercial sales moved Protagonist Therapeutics ($PTGX) into the black in Q2 2026, with profit at $162.8 million compared with a $34.8 million loss in the same period a year earlier.
The next confirmable event is rusfertide's PDUFA goal date in August, when the FDA is scheduled to rule on the injectable's new drug application for polycythemia vera.
The numbers License and collaboration revenue came in at $213.5 million for the quarter.
Of that, $192.4 million traces to proportional recognition of Takeda's $200 million opt-out payment made in April, a single deal event rather than a commercial book building on itself.
Keep reading